El interés en corto de Avidity Biosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Avidity Biosciences. Los datos de interés en corto se actualizan cada dos semanas.

Avidity Biosciences (NASDAQ:RNA) Bolsa, Informe de interés en corto

AVIDITY BIOSCIENCES INC

Avidity Biosciences

Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Avidity Biosciences Inc

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics Inc

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

HC Wainwright &amp; Co. analyst Andrew Fein maintains Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and lowers the price target from $72 to $68.

News

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Avidity Biosciences, Lowers Price Target to $68

Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and maintains $65 price target.

Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target

Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(0.91) by 1.1 percent. This is a 13.92 percent decrease over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $1.57 million which missed the analyst consensus estimate of $1.90 million by 17.21 percent. This is a 55.60 percent decrease over sales of $3.54 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Avidity Biosciences Q1 EPS $(0.90) Beats $(0.91) Estimate, Sales $1.57M Miss $1.90M Estimate

12 analysts have shared their evaluations of Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $64.67, a high estimate of $72.00, and a low estimate of $48.00. Witnessing a positive shift, the current average has risen by 1.57% from the previous average price target of $63.67.
<img src="https://www.benzinga.com/files/images/story/2025/1746619285_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Avidity Biosciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Avidity Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Avidity Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Avidity Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>Discovering Avidity Biosciences: A Closer Look</h2>
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
<h3>Unraveling the Financial Story of Avidity Biosciences</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, Avidity Biosciences showcased positive performance, achieving a revenue growth rate of 35.57% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Avidity Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -3439.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Avidity Biosciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -6.98%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Avidity Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.38%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

12 Analysts Assess Avidity Biosciences: What You Need To Know

WIIM

BHVN

CAPR

CRSP

MARA

NVAX

SLDB

SRPT

TSHA

XNCR

Shares of vaccine and gene therapy stocks are trading lower after FDA Commissioner Marty Makary reportedly named Vinay Prasad as director of the Center for Biologics and Research.

<a href="https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics" title="https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics">https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics</a>

Biotech

General

DSGN

MRNA

PTCT

'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law

In the last three months, 13 analysts have published ratings on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.38, along with a high estimate of $72.00 and a low estimate of $48.00. This current average reflects an increase of 1.05% from the previous average price target of $64.70. 
<img src="https://www.benzinga.com/files/images/story/2025/1744207282_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Avidity Biosciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Stringer &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Joseph Stringer &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $60.00&#x7C;$60.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C; 
&#x7C;Keay Nakae &#x7C;Chardan Capital &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C; 
&#x7C;Geoff Meacham &#x7C;Citigroup &#x7C;Announces &#x7C;Buy &#x7C; $70.00&#x7C;- &#x7C; 
&#x7C;Kostas Biliouris &#x7C;BMO Capital &#x7C;Announces &#x7C;Outperform &#x7C; $72.00&#x7C;- &#x7C; 
&#x7C;Geoff Meacham &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $48.00&#x7C;$51.00 &#x7C; 
&#x7C;Louise Chen &#x7C;Scotiabank &#x7C;Announces &#x7C;Sector Outperform&#x7C; $70.00&#x7C;- &#x7C; 
&#x7C;Gena Wang &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $57.00&#x7C;$63.00 &#x7C; 
&#x7C;Keay Nakae &#x7C;Chardan Capital &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $67.00&#x7C;$67.00 &#x7C; 
&#x7C;Andrew Fein &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $72.00&#x7C;$72.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Avidity Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Avidity Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Avidity Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>Unveiling the Story Behind Avidity Biosciences</h2>
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
<h3>Financial Insights: Avidity Biosciences</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Avidity Biosciences showcased positive performance, achieving a revenue growth rate of 35.57% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Avidity Biosciences's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3439.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Avidity Biosciences's ROE stands out, surpassing industry averages. With an impressive ROE of -6.98%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Avidity Biosciences's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.38%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and maintains $60 price target.

Reiteration

Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target

Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan&nbsp;

Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran For Myotonic Dystrophy Type 1

Avidity Biosciences Finalizes Enrollment In Biomarker Cohort Of Phase 1/2 FORTITUDE™ Trial For Delpacibart Braxlosiran  In Individuals With Facioscapulohumeral Muscular Dystrophy

During the last three months, 13 analysts shared their evaluations of Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of $72.00, and a low estimate of $48.00. Marking an increase of 1.67%, the current average surpasses the previous average price target of $65.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1742335223_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Avidity Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Kostas Biliouris</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$72.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$72.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avidity Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Avidity Biosciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Avidity Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>Discovering Avidity Biosciences: A Closer Look</h2>
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
<h3>Breaking Down Avidity Biosciences's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Avidity Biosciences's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 35.57%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -3439.52%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -6.98%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -6.38%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 13 Analyst Projections For Avidity Biosciences

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy and maintains $72 price target.

HC Wainwright & Co. Reiterates Buy on Avidity Biosciences, Maintains $72 Price Target

Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) released on Monday del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy amenable to <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">exon 44 skipping (DMD44)</a>.
Del-zota is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal and cardiac muscle tissue to specifically skip exon 44 of the dystrophin gene and enable the production of near-full-length dystrophin.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44286904/dyne-therapeutics-4-3-billion-peak-sales-potential-analyst-highlights-key-strengths-and-risks" rel="noreferrer noopener">Dyne Therapeutics&#8217; $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks</a>
The data presented highlighted the consistent data across all parameters in both the 5 mg/kg and 10 mg/kg cohorts of <a href="https://www.benzinga.com/pressreleases/25/03/n44352786/avidity-biosciences-announces-positive-topline-del-zota-data-demonstrating-consistent-statisticall" target="_blank" rel="noreferrer noopener">del-zota, including</a>:
<ul>
<li>Targeted delivery of PMOs resulting in tissue concentrations of approximately 200nM in skeletal muscle;</li>
<li>Statistically significant increases of approximately 40% in exon 44 skipping.</li>
<li>Statistically significant increase of approximately 25% of normal in dystrophin production and restored total dystrophin up to 58% of normal.</li>
<li>Reduction in creatine kinase levels to near normal with greater than 80% reductions compared to baseline:
<ul>
<li>Similarly, placebo participants demonstrated a reduction in creatine kinase levels to near normal upon treatment with del-zota.</li>
<li>Significant reductions in creatine kinase levels were sustained in the EXPLORE44-OLE trial with continued treatment up to one year.</li>
</ul>
</li>
<li>Del-zota demonstrated favorable safety and tolerability at both doses, with most treatment emergent adverse events (TEAEs) mild or moderate.</li>
</ul>
Based on the consistent data between the 5 mg/kg every six weeks and the 10mg/kg every eight weeks groups across all parameters, Avidity has selected the dose of 5 mg/kg every six weeks of del-zota for the Biologics License Application (BLA) submission and future clinical studies.
Participants receiving the 10 mg/kg dose in the EXPLORE44-OLE trial are being transitioned to 5 mg/kg every six weeks.&nbsp;
The company plans to present functional data in the fourth quarter of 2025 and is on track for a BLA submission by the end of 2025 for accelerated approval of 5 mg/kg of del-zota every six weeks in DMD44.
Following alignment with the FDA on the accelerated approval path late last year, including dose selection, Avidity&#8217;s commercial preparations for a potential U.S. launch of del-zota in DMD44 are well underway.
RNA Price Action: Avidity Biosciences stock is up 6.56% at $33.15 at publication Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44357988/zoom-introduces-customizable-ai-companion-with-new-add-ons-for-businesses" target="_blank" rel="noreferrer noopener">Zoom Introduces Customizable AI Companion With New Add-Ons For Businesses</a></li>
</ul>
Photo: Shutterstock

Health Care

Movers

Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025

<ul>
<li>On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44</li>
<li>Consistent favorable safety and tolerability across del-zota dose cohorts&nbsp;</li>
<li>Plan to present functional data in fourth quarter of 2025</li>
</ul>

Avidity Biosciences Announced Del-Zota Topline Data From The Phase 1/2 Explore44 Trial For Duchenne Muscular Dystrophy Amenable To Exon 44 Skipping, Demonstrating Consistent, Statistically Significant Improvements In Dystrophin, Exon Skipping And Creatine Kinase As Well As Favorable Safety And Tolerability

Citigroup analyst Geoff Meacham initiates coverage on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy rating and announces Price Target of $70.

Initiation

Citigroup Initiates Coverage On Avidity Biosciences with Buy Rating, Announces Price Target of $70

On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>), focused on developing therapies for genetically <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">driven neuromuscular diseases</a>.
The company&#8217;s FORCE platform is designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS).
Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
In January, Dyne Therapeutics revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101, the company&#8217;s lead candidate, in patients with&nbsp;<a target="_blank" href="https://www.benzinga.com/25/01/42923575/why-is-neuromuscular-focused-dyne-therapeutics-stock-trading-lower-on-friday" rel="noreferrer noopener">myotonic dystrophy type 1 (DM1)</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40692261/muscle-disease-drug-developer-dyne-therapeutics-stock-plunges-after-updated-data-from-duchenne-mu" rel="noreferrer noopener">Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy</a>
Dyne plans to begin a global Registrational Expansion Cohort with the potential to support a submission for U.S. Accelerated Approval based on biomarker and functional data in H1 2026.
Dyne leverages TfR1 Fab-conjugation for drug delivery to muscles. TfR1 is highly expressed in muscle cells. BMO analyst Kostas Biliouris acknowledges potential safety risks associated with TfR1-targeting (anemia, hemorrhage, kidney injury) but notes that the safety in Dyne&#8217;s clinical data appears acceptable.
Analyst Biliouris says Dyne&#8217;s major catalyst and investor debate revolves around the FDA&#8217;s decision on the DM1 regulatory pathway, as this dictates whether Dyne could enter the DM1 market concurrently or behind its competitor Avidity Biosciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>)
BMO assumes a traditional approval pathway and sees the DM1 market as large enough to accommodate multiple players, and Dyne could differentiate via potential CNS benefits.
BMO has initiated with an Outperform rating and <a target="_blank" href="https://www.benzinga.com/quote/DYN/analyst-ratings" rel="noreferrer noopener">a price target of $50</a>.
The analyst models around $4.3 billion DYNE-101 peak-risk unadjusted WW sales in 2035.
Price Action: DYN stock is up 2.16% at $12.29 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44283520/viking-holdings-to-see-strong-2025-business-despite-february-slowdown-says-analyst" target="_blank" rel="noreferrer noopener">Viking Holdings&#8217; 2025 Nearly Sold Out, But Goldman Sachs Seeks More Pricing Clarity For 2026</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Equities

Trading Ideas

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

Press Releases

Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases

Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy

Comments

Avidity Biosciences

Interés en corto

Avidity Biosciences (NASDAQ:RNA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL